Atrial fibrillation is a common heart condition characterized by a rapid, irregular heartbeat stemming from the heart's upper ...

Commercially launched in the U.S. in November 2025, TONMYA (cyclobenzaprine HCl sublingual tablets) for long-term daily dosing at bedtime is the first new FDA-approved treatment for fibromyalgia in ad ...

The influencer died suddenly on Feb. 21 at age 25 ...

Cardiovascular disease remains the leading cause of mortality worldwide, necessitating deeper insights into its molecular ...

STEMI patients without standard modifiable CV risk factors face higher 30-day mortality compared with those with at least 1 risk factor.

The death rate of severe heart attacks has risen over the past decade among Americans under 55, new research shows.

New data suggest Twist1-driven atherosclerotic plaques may enhance stability rather than rupture risk. Learn how this ...

Advances in cancer treatment mean that more people than ever are surviving the disease. However, some of the most effective ...

Heart attack death rates rose by 1.2% among adults younger than age 55 who were hospitalized between 2011 and 2022 with a first severe heart attack, according to a February study published in the ...

Patients with pulmonary adenocarcinoma consulted the neurology department due to multiple initial symptoms of cerebral ischaemia. Examination of each patient revealed pulmonary embolism, the ...

A new report suggests that millions of U.S. adults are unaware they may have undiagnosed cardiovascular risk factors that ...

Ozempic (R) was approved by Health Canada in 2018. Ozempic (R) is indicated for the once-weekly treatment of adult patients with type 2 diabetes mellitus to improve glycemic control.